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Stroke Trials Archive (VISTA) 12 to assess any deviations in the response profiles found. This validation study sought to capture the relationship between the profiles of NIHSS items and the response patterns that are associated with both functional and neurological outcome and death.
Methods
Data Source
We conducted a retrospective analysis on pooled data from randomized clinical trials obtained from VISTA (http://www.vistacollaboration.org/). 12 VISTA is a collaborative registry that collates and provides access to completed acute stroke trials' data (from year 1998-2008), anonymized in relation to patients and trials' identity, for novel exploratory analyses. It is worth noting that VISTA data do not include trials of thrombolysis therapy, per se, although thrombolysis was commonly used as standard therapy, where appropriate. All patients with stroke were treated as per institutional practice and stroke guidelines acceptable at the point of trial conduct. Conduct and reporting of our analysis are in accordance with the Strengthening the Reporting of Observational Studies in Epidemiology guidelines for cohort studies. 13 
Participants and Variables
We selected patients who had been randomized to receive placebo or any drug now known to possess no confirmed action on stroke outcome. We included patients for whom we had baseline demographics and outcome information: individual components of the baseline NIHSS, age, sex, thrombolysis administration as standard of care, comorbidities, occurrence of adverse events, and serious adverse events, mortality by 90 days and modified Rankin Scale (mRS) at day 90.
Statistical Methods
We applied the probabilities of profile membership generated by Sucharew et al 7 to our data to observe how their profiles' performances in an acute cohort of patients. These were labeled a-NIHSS item profiles. Descriptive statistics were generated for the entire cohort and each profile separately. We described mean (SD) or median (interquartile range) for continuous variables and count (percentage) for categorical variables.
Validation was performed by assessing discrimination and calibration of the NIHSS item profiles' association with outcome within the VISTA data. Outcome measures assessed at 90 days included the full distribution of the mRS, favorable mRS (mRS, 0-1), mortality, and time to death. Odds ratios and 95% confidence intervals of the outcome measures were obtained using ordinal logistic regression (for ordinal outcome measure) and binary logistic regression (for dichotomized outcome measure). The associated P values calculated using the Cochrane-Mantel-Haenszel test. Time to death was investigated using Kaplan-Meir survival curves and analyzed using Cox proportional hazards model. Analyses were adjusted for age and thrombolysis treatment. 14, 15 Because the a-NIHSS item classification was derived from the probabilities of the original profile membership generated using retrospective data (by Sucharew et al 7 ) , we ran an independent LCA on the acute cohort data to identify our own symptom profiles, labeled b-NIHSS item profiles. Each individual NIHSS attribute was dichotomized as normal (0) or abnormal (≥1). Because the latent class model requires the number of classes to be prespecified, we initially specified 6 classes to see whether the b-NIHSS group in a similar manner to the grouping of retrospective NIHSS. 7 We intended that if b-NIHSS item profiles were widely disparate to those identified previously, we would repeat the LCA starting with specifying 2 classes and increasing these in a stepwise fashion. The number of classes is considered optimal at the point when no statistically significant improvement in model fit is noted with an increase in the number of classes. We calculated and compared descriptive statistics and analyzed the association of the b-NIHSS item profiles with each outcome measure, as mentioned above. The symptom profiles' ability to discriminate for dichotomized outcomes were evaluated using the c-statistics. Calibration was assessed with Hosmer-Lemeshow goodness-of-fit test. All analyses were undertaken using SAS version 9.3 (SAS Institute, Inc, Cary, NC).
Results
We obtained data for 10 271 patients with acute ischemic stroke, who had full set of data on individual items of the baseline NIHSS and outcome by 90 days (Figure 1 ). The cohort has median age of 72 (interquartile range, 62-79) years and baseline NIHSS of 13 (9) (10) (11) (12) (13) (14) (15) (16) (17) . Baseline characteristics of the cohort are shown in Table 1 .
By applying the probabilities of profile membership to the VISTA cohort, we replicated the 6 profiles identified by Sucharew et al 7 (profiles A to F, denoted a-NIHSS item profiles). Median baseline NIHSS decreased from most severe profile A, to mild profile F, with (median [interquartile range]) 19 (15) (16) (17) (18) (19) (20) (21) (22) ) and 4 (3-7), respectively. The profiles are shown in Figure 2 and in Figure I in the online-only Data Supplement. Individual a-NIHSS items that contributed into a specific profile are described in Table 2 . The profiles that represented greater stroke severity, as indicated by the higher baseline NIHSS, included patients who were older and were more likely to have atrial fibrillation, chronic heart failure, and previous myocardial infarction. There were also notable differences in the use of thrombolysis treatment across the profiles, where patients in the more severe profiles were more likely to receive the treatment (Table 1) . Two profiles falling between the extremes (ie, profiles C and D), were found to have near-similar median NIHSS scores, 10 (8-12) and 9 (7-11), respectively.
Ordinal analysis of mRS at day 90 showed increasing odds of better outcome across the profiles in a stepwise manner, adjusted for age and thrombolysis treatment (Table 3 ; Figure  II in the online-only Data Supplement). Similar patterns were observed for mRS of favorable outcome at 90 days, with adjustment as above (Table 3) . Profiles C and D, which had near-similar median NIHSS, had significant different 90-day mortality and survival rates, adjusted for age and thrombolysis (Table 3) . Taking profile A as reference, profile C was associated with 43% reduction in the risk of 90-day mortality, whereas profile D was associated with 81% reduction. Similar patterns were seen in overall survival with the reduction in the risk of death for profiles C and D were 41% and 78%, respectively, when compared with profile A (Table 3 ; Figure 3 ). The discrimination of the a-NIHSS item profiles for dichotomized outcome was modest with c-statistics of 0.71 (95% confidence interval, 0.70-0.72) and 0.74 (0.73-0.75) for favorable mRS outcome at 90 days and mortality, respectively. The calibration was good (P=0.12 and P=0.22, respectively, for the Hosmer-Lemeshow test).
To validate these results, independent LCA was applied to our cohort's data. Six distinct b-NIHSS item profiles (profiles 1-6) were identified, with the median NIHSS total score decreased across the profiles (Figure 2 ; Figure III in the online-only Data Supplement). Individual b-NIHSS items that contributed into a specific profile are described in Table 2 . The baseline characteristics of the cohort by b-NIHSS item profiles are shown in Table I in the online-only Data Supplement. Patients grouped into profile 1 tended to be older and were more likely to have atrial fibrillation, acute myocardial infarction, and chronic heart failure. Profiles 3 and 4 (that were equivalent to profiles C and D in a-NIHSS item profiles) had different median NIHSS, with (median [interquartile range]) 13 (10-16) and 8 (6-10), respectively. Profiles 4 and 5 had median NIHSS of 8.
Consistent with a-NIHSS item profiles, b-NIHSS item profiles have similar outcome patterns for ordinal analysis of improved outcome using mRS at full distribution, and dichotomized outcomes at 90 days, after adjustment for age and thrombolysis treatment (Table II; 
Discussion
Our present analysis has externally validated the original LCA derived within a population using retrospective NIHSS using clinical trial data and prospectively obtained NIHSS scores. We have confirmed that the LCA method of analyzing NIHSS items in patients with acute stroke offers an alternative approach for summarizing prognostic information, in terms of functional and mortality outcomes, compared with using raw NIHSS total score. Consistent with the previous study, 7 our patients with high baseline NIHSS score were more likely to fall into profiles A and B and were more likely to experience worse outcomes when compared with patients in other profiles. Patients in these 2 severe profiles tended to be older and have history of atrial fibrillation, ischemic heart disease, and chronic heart failure. Also as before, 2 symptom profiles possessing comparable median NIHSS (ie, profiles C and D) had divergent outcomes. Of note, patients in profile C were more likely to have aphasia when compared with patients in profile D. This emphasizes the concerns of considering individual NIHSS components as equal, such that a single point on NIHSS for aphasia may have dramatic effect on outcome when compared with a single point on NIHSS for limb signs. This also confirms the clinical suspicion that aphasia after stroke influences prognosis and recovery. 16 The further validation study using independent LCA on our data revealed similar findings, which suggests that we may be capturing the true response patterns of the symptom profiles that are associated with functional outcomes and death. Thus, the NIHSS symptom profiles may be clinically useful for predicting prognosis. This approach may also have a place in future clinical trials design, whereby certain symptom profiles can be set as inclusion or exclusion criteria, or to aid prognostic subgroup analysis, rather than simply relying upon total NIHSS score.
Strengths of this analysis include the large sample size recruited from rigorous clinical trials and the prospective nature of the NIHSS data collected. In addition, we explored the discrimination and calibration power of the NIHSS item profiles to predict favorable mRS outcome and mortality at 90 days, thus extending its prognostic role and generalizability. Because we were satisfied that the NIHSS item profiles were largely similar to the LCA on 2 independent data sets, and that the performance of the original NIHSS item profiles is good in a second data set, we are content to recommend the use of the original set of NIHSS item profiles. Our analysis also has potential limitations. We acknowledge that there may be potential bias in outcome analysis when using pooled data from several trials with different interventions and end points. Even if only placebo or drugs without confirmed action on stroke outcome were used, bias still exists. However, using intracluster correlation coefficients, Frank et al 17 have demonstrated that analyses using pooled data from multiple trials in VISTA have low overall variation in outcome. Our cohort also represents a highly selected group of patients based on individual trials' eligibility criteria. The patients were more likely arriving to medical attention earlier and with more severe infarcts. For this validation study, NIHSS items were dichotomized, and the cohort was limited to those with full breakdown of baseline NIHSS items data, which may limit the sensitivity because of loss of information. 7 However, this analytic method enables the probability of an abnormal response for each NIHSS items to be grouped into meaningful profile patterns. The small number of patients with mild stroke (ie, NIHSS ≤5) does not allow us to compare the performance of the symptom profiles among those patients. The absence of prestroke functional status (ie, prestroke mRS) data precludes pre-and poststroke functional comparison. However, we speculate that patients included in the acute stroke trials usually have good prestroke mRS (as often good prestroke mRS is a prerequisite entry criteria for acute stroke trials). One of our outcome measures was full distribution mRS at 90 days using ordinal logistic regression with the proportional odds model. Although there are criticisms that the nature of the mRS is often not meet the ordinality assumption, this analysis approach has gained popularity in recent years. 18, 19 Limitations of the LCA method to develop the NIHSS item profiles have been discussed elsewhere. 7 Briefly, LCA method requires a predetermined of the numbers of classes in the population of interest. Although the number of classes proposed was checked, it was possible that we under-or overestimated the number of true classes. The P values for the relationship across the a-NIHSS item profiles for different outcomes described above are <0.001. CI indicates confidence interval; HR, hazard ratios; mRS, modified Rankin Scale; NIHSS, National Institutes of Health Stroke Scale; OR, odd ratios; and Ref, reference. 
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In conclusion, our results demonstrate the reliability of the NIHSS item profiles to capture the true response patterns that are associated with functional and mortality outcomes in an acute stroke cohort. The NIHSS symptom profiles might be clinically useful for prognostication and could potentially be applied in future clinical trial design. 
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